The investigation, published in Frontiers in Cell and Developmental Biology, took a comprehensive approach to understanding CDKN2A’s role in colorectal cancer. The researchers began by mining vast transcriptomic and clinical datasets from The Cancer Genome Atlas and the Gene Expression Omnibus databases. They focused on 688 human radiation response-related genes, identified by integrating five GEO datasets that compared gene expression profiles between radiosensitive and radioresistant cancer cells across multiple malignancies. From this pool, they pinpointed 495 genes differentially expressed between tumor and normal tissues and 36 genes significantly linked to overall survival. The intersection yielded 28 key genes, and among these, CDKN2A stood out as the hub gene, exhibiting the most extensive interactions with other prognosis-related radiation response genes in the protein-protein interaction network.

What makes CDKN2A particularly intriguing is its paradoxical nature. The gene encodes the p16 protein, which normally functions as a tumor suppressor by inhibiting CDK4/6 kinase activity, thereby maintaining cell cycle arrest in the G1 phase. It can also initiate DNA repair or apoptosis by activating p53. Yet in colorectal cancer, the researchers found that CDKN2A is consistently overexpressed rather than deleted or mutated. Bulk and single-cell transcriptome analyses, along with immunohistochemistry, revealed elevated CDKN2A expression in tumor specimens. The mutation frequency of CDKN2A in these tumors was remarkably low, approximately 1 percent, suggesting that overexpression rather than genetic alteration drives the gene’s malignant role. Single-cell analysis identified 21 cell clusters comprising 12 cell types in colorectal cancer tissue, with three distinct tumor cell subtypes showing heterogeneous CDKN2A expression, particularly high in the C6 and C9 subtypes.

The clinical implications are striking. The researchers obtained tumor samples from 46 patients with rectal cancer prior to treatment, all of whom received neoadjuvant long-course chemoradiotherapy at a radiation dose of 50.4 Gy in 28 fractions combined with fluorouracil and leucovorin calcium chemotherapy, followed by standardized surgery. Patients whose tumors failed to respond to neoadjuvant chemoradiotherapy had significantly higher CDKN2A expression than those who responded, with a P value of 0.039. The team then reviewed postoperative pathology and follow-up data from 290 rectal cancer patients who underwent surgery and 5-fluorouracil-based adjuvant treatment. Those who experienced recurrence showed elevated CDKN2A expression compared with those who did not, at P equal to 0.037. These findings establish CDKN2A overexpression as a clinical marker of treatment failure and disease return.

To probe the biological function of CDKN2A, the researchers turned to laboratory experiments using the human colorectal cancer cell line HCT 116. They deployed short hairpin RNA to knock down CDKN2A expression, with the most effective construct reducing mRNA levels dramatically as confirmed by reverse-transcription PCR and Western blot. The results were unequivocal: CDKN2A knockdown led to a marked decrease in proliferation, invasion, and migration capabilities. When combined with X-ray irradiation at 4 Gy, the effect was amplified. Clonogenic assays demonstrated that the clone formation rate following combined irradiation was significantly diminished in the CDKN2A knockdown group compared with controls. Wound-healing and transwell assays further confirmed that reducing CDKN2A expression impaired the migratory and invasive capacity of irradiated cells, supporting a contributory role for CDKN2A in radiation resistance.

The researchers extended their findings into living systems by constructing subcutaneous tumor models in female BALB/c mice. Tumors with CDKN2A knockdown grew more slowly after irradiation than control tumors. Immunohistochemistry revealed that the knockdown group had significantly more necrosis after irradiation, with P values below 0.05. These in vivo results corroborate the in vitro data, demonstrating that suppressing CDKN2A enhances the radiosensitivity of colorectal cancer tumors in living organisms, not just in culture dishes.

Beyond radiation resistance, CDKN2A overexpression carries a dire prognostic signal. Patients with high CDKN2A expression demonstrated inferior overall survival, progression-free survival, recurrence-free survival, and disease-free survival. The gene’s expression correlated with multiple aggressive clinicopathological features, including age at or below 65 years, lymph node metastasis, distant metastasis, and high TNM stage. These associations position CDKN2A as both a prognostic biomarker and a participant in malignant progression, linking its overexpression to the most invasive and lethal forms of the disease.

Perhaps most remarkably, CDKN2A appears to sculpt the tumor immune microenvironment into an immunosuppressive state. Using xCell, CIBERSORT, and EPIC computational methods to assess immune cell infiltration, the researchers found that CDKN2A expression was positively correlated with the infiltration levels of M2-type macrophages, monocytes, and regulatory T-cells, all of which promote tumor progression and immune escape. Conversely, CDKN2A expression was negatively linked to CD8-positive T-cell infiltration, the core effector cells of antitumor immunity. Single-cell transcriptomics revealed that tumor cell subtypes with high CDKN2A expression had weak interactions with CD8-positive T-cells but strong interactions with fibroblasts and endothelial cells, further reinforcing the immunosuppressive architecture. Molecular analysis showed that levels of immune inhibitors such as VTCN1, TGFB1, PDCD1, and CD274 were positively correlated with CDKN2A expression, along with cytokine ligands and receptors including CCL17, CXCL16, and CXCR5.

The immunotherapy prediction results add another layer of complexity. Analysis using The Cancer Immunome Atlas database suggested that patients with elevated CDKN2A expression showed a greater likelihood of responding to anti-PD-L1 therapy but a diminished likelihood of responding to anti-PD-1 therapy, while response to CTLA-4 was unrelated to CDKN2A expression level. The researchers speculate that in tumors with high CDKN2A expression, low CD8-positive T-cell infiltration combined with a highly activated PD-1/PD-L1 pathway leads to T-cell depletion. Anti-PD-1 treatment does not reverse this depletion, whereas PD-L1 inhibitors may reverse the immunosuppressive microenvironment. Additionally, when using PD-L1 inhibitors, PD-L2 can be retained to combine with repulsive guidance molecule B, thereby promoting T-cell expansion. In patients with low CDKN2A expression, the antitumor immune microenvironment is relatively favorable, and PD-1 inhibitors can continuously activate the tumor-killing effect of CD8-positive T-cells. These findings suggest that CDKN2A may eventually serve as a biomarker to guide clinical selection of immunotherapeutic drugs.

Functional enrichment analysis through Gene Ontology and KEGG databases illuminated the biological pathways through which CDKN2A exerts its effects. Elevated CDKN2A expression was linked to transcriptional regulation, amino acid metabolism, lipid metabolism, protein folding, and the TGF-beta signaling pathway. The gene’s function relates to intermediate filament cytoskeleton organization, regulation of macromolecule biosynthetic processes, DNA-templated regulation of transcription, MHC class I receptor activity, and N-methyltransferase activity. Drug sensitivity analysis revealed that tumors with high CDKN2A expression are more likely to be resistant to oxaliplatin and 5-fluorouracil, the two representative chemotherapy drugs used in colorectal cancer, but may be sensitive to dasatinib, lapatinib, and GDC-0879. The resistance to 5-fluorouracil may stem from the G1 phase arrest caused by CDKN2A, rendering the S-phase-specific drug ineffective. The resistance to oxaliplatin may relate to cell cycle arrest and enhanced DNA damage repair. The researchers propose that the p16 protein encoded by CDKN2A causes G1 phase arrest under stress, reducing DNA damage in adverse environments and providing time for repair, which might explain why patients with high CDKN2A expression are insensitive to radiotherapy, which mainly acts on cells in the G2/M phases undergoing mitosis.

The study’s conclusions carry profound implications for clinical management. Targeted inhibition of CDKN2A enhances the sensitivity of tumor cells to radiotherapy and may modulate the immunosuppressive state, potentially providing a new strategy for improving treatment effectiveness in colorectal cancer patients. The combination of radiation therapy with CDKN2A-targeted intervention represents a promising therapeutic avenue that could transform unresectable tumors into resectable ones and boost the pathological complete response rate in rectal cancer. However, the researchers acknowledge important limitations. The main conclusions are based on retrospective analysis of public databases, and additional prospective clinical studies, gain-of-function and rescue experiments in colorectal cancer cell lines with low endogenous CDKN2A expression are needed. The use of a single cell line limits generalizability, and the dual-tumor animal models may lead to mutual influences between tumors through cytokines and other mechanisms. The molecular mechanisms by which CDKN2A affects radiotherapy sensitivity and the immune microenvironment have not been fully elucidated, and the TGF-beta pathway remains a bioinformatic prediction without experimental validation. Moreover, the assertion that colorectal tumors with high CDKN2A expression may respond to agents such as dasatinib and lapatinib is based on algorithm predictions requiring clinical verification. More experimental and clinical studies are still needed to distinguish the similarities and differences between colon cancer and rectal cancer, as the correlation between CDKN2A and radiotherapy sensitivity has only been validated in the rectal cancer cohort. Nevertheless, this investigation provides compelling evidence supporting CDKN2A as a potential therapeutic target and prognostic biomarker, opening a new frontier in the fight against one of humanity’s deadliest cancers.

Subject of Research: Association of CDKN2A overexpression with poor prognosis, radioresistance, and immunosuppression in colorectal cancer

Article Title: Association of CDKN2A overexpression with poor prognosis, radioresistance, and immunosuppression in colorectal cancer

Article References: Lin, Y., Wang, Z., Ju, G., Zhang, Y., Huang, Z., Liu, S., Xu, B., & Zhan, Z. (2026). Association of CDKN2A overexpression with poor prognosis, radioresistance, and immunosuppression in colorectal cancer. Frontiers in Cell and Developmental Biology, 14, Article 1955910. https://doi.org/10.3389/fcell.2026.1955910

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1955910

Keywords: Association, CDKN2A, overexpression, poor, prognosis, radioresistance, immunosuppression, colorectal, cancer, scientific research

The investigation began with a straightforward question: what molecular differences separate cancer cells that die under radiation from those that persist? To find out, the researchers performed RNA sequencing transcriptomic profiling, comparing parental head and neck squamous cell carcinoma cell lines with sublines that had been made radioresistant through repeated exposure. Among the genes that stood out as strongly upregulated in the resistant cells was DRP1, the master regulator of mitochondrial fission. Mitochondria are dynamic organelles that continuously divide and fuse, and this flux, sometimes described as mitochondrial plasticity, allows cells to adapt their energy metabolism to stress. In radioresistant cancer cells, that adaptability appears to depend heavily on DRP1-driven fission, which keeps mitochondria fragmented and metabolically flexible in the face of radiation-induced injury.

The clinical relevance of this observation was reinforced by two independent lines of evidence. In publicly available head and neck cancer datasets, patients whose tumors expressed higher levels of DRP1 had poorer overall survival. The team then validated the finding in an exploratory institutional cohort of patients treated with postoperative adjuvant or definitive radical radiotherapy, where elevated DRP1 again tracked with adverse radiotherapy-related outcomes. While these associations are correlational and require confirmation in larger prospective studies, they suggested that DRP1 is not merely a laboratory curiosity but a marker linked to how real patients fare under radiation treatment.

Mechanistically, the study revealed a striking chain of events that connects mitochondrial shape to radiation sensitivity. Radiation kills cells largely by generating reactive oxygen species, highly reactive molecules that shred DNA beyond repair. The researchers found that when DRP1 was knocked down in cancer cells, mitochondria underwent hyperfusion, fusing into elongated networks instead of fragmenting. This shift triggered a dramatic surge in radiation-induced reactive oxygen species, overwhelming the cell’s antioxidant defenses and leaving behind substantially more residual DNA damage after irradiation. In other words, fragmented mitochondria appear to act as a buffer that helps cancer cells absorb and neutralize the oxidative blast of radiation; remove that buffer, and the oxidative assault lands with full force.

To confirm that oxidative stress was truly the engine of this radiosensitization, the researchers added N-acetyl-L-cysteine, a well-known antioxidant precursor of glutathione, to the experiments. The antioxidant attenuated the radiosensitizing effect of DRP1 loss, supporting the interpretation that the excess reactive oxygen species generated in DRP1-depleted cells is what drives them toward death after radiation. Untargeted metabolomics then mapped the broader metabolic consequences of DRP1 depletion, revealing changes in metabolite abundance and pathway enrichment related to amino acid metabolism, glutathione synthesis, and bioenergetic homeostasis. Together, these data sketch a coherent picture: DRP1 maintains the metabolic and antioxidant machinery that radioresistant cells rely on, and dismantling that machinery leaves tumors exposed.

Crucially, the team showed that the phenomenon is not confined to genetic manipulation. Two pharmacological inhibitors, Mdivi-1, a widely studied fission blocker, and P110, a more selective peptide inhibitor that targets the interaction between DRP1 and its mitochondrial receptor, reproduced the key phenotypes of DRP1 knockdown in vitro. Clonogenic survival assays, which measure a cell’s ability to divide and form colonies after radiation, showed reduced survival when the inhibitors were combined with radiation. Radiation-induced DNA damage accumulated to a greater extent, and mitochondrial metabolism shifted in ways consistent with the loss of fission-dependent plasticity. The fact that two chemically distinct inhibitors produced matching results strengthens the case that DRP1 itself, rather than an off-target effect, underlies the radiosensitization.

The most compelling evidence came from animal models. In mice bearing subcutaneous xenografts derived from CAL27 IR-R, a head and neck cancer subline engineered through acquired radioresistance, adding Mdivi-1 to radiotherapy enhanced the antitumor effect compared with radiation alone. The researchers then turned to a complementary and arguably more clinically faithful model: a syngeneic orthotopic MOC-1 tongue tumor model, in which immunocompetent mice carry tumors in the tongue itself, mimicking the anatomical and immune context of human head and neck cancer. Once again, the combination of Mdivi-1 and radiation outperformed radiation alone. Histological examination of major organs at the study endpoint revealed no overt evidence of treatment-related injury, an early but encouraging signal regarding tolerability.

The concept of targeting mitochondrial dynamics in cancer is part of a broader shift in oncology research away from attacking tumors solely through their genomes and toward exploiting their metabolic vulnerabilities. Radiation oncology has long sought reliable radiosensitizers, agents that can be given alongside radiation to tip the balance from survival to death in tumor cells while sparing normal tissue. Many candidates have faltered in translation, often because their mechanisms are too narrow or their toxicity windows too slim. A fission inhibitor offers a different logic: rather than adding damage, it removes a defense, preventing cancer cells from flexibly reconfiguring their mitochondria to detoxify the reactive oxygen species that radiation generates. Because the strategy was effective in both an acquired-resistance model and an immunocompetent orthotopic model, it addresses two of the most common reasons preclinical radiosensitizers fail clinically.

Important caveats remain before this approach reaches patients. The clinical cohort linking DRP1 to outcomes was exploratory, and the safety findings in mice, while reassuring, represent only an initial assessment at a single study endpoint. Mdivi-1 itself has off-target effects described in the broader literature, which is why the confirmation with the more selective P110 peptide matters, and clinical-grade DRP1 inhibitors would need careful development. Dosing, scheduling relative to radiation fractions, and potential effects on normal tissues that depend on mitochondrial remodeling all require further study. Still, the internal consistency of the work, from transcriptomics through metabolomics, mechanistic cell biology, pharmacology, and two independent in vivo models, gives the hypothesis unusual robustness at the preclinical stage.

If subsequent studies confirm these results, DRP1 could join a growing list of metabolic regulators whose inhibition converts resistant tumors into treatable ones. For patients with head and neck squamous cell carcinoma, where radioresistance is a primary cause of treatment failure and options after recurrence are limited, a drug that strips away mitochondrial plasticity could meaningfully expand the therapeutic window of radiation. The study, funded by the National Natural Science Foundation of China and regional research programs in Guangdong, was conducted under institutional ethical approval for both animal experiments and patient tissue use. Its authors describe the findings as a preclinical rationale for further investigation of DRP1-targeted radiosensitization strategies, and the field will now watch to see whether this mitochondrial vulnerability can be translated into a clinical advantage.

Subject of Research: DRP1-mediated mitochondrial fission as a driver of radioresistance in head and neck squamous cell carcinoma

Article Title: Targeting DRP1 to limit mitochondrial plasticity overcomes radiation resistance in head and neck squamous cell carcinoma

Article References: Zheng, Y., Li, T., Li, Y., Yang, Y., Li, G., Xu, L., Guan, T., Huang, L., Fang, Y., Zhang, Y., Li, C., Yang, S., Li, H., Zhou, M., & Liu, Z. (2026). Targeting DRP1 to limit mitochondrial plasticity overcomes radiation resistance in head and neck squamous cell carcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09083-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09083-0

Keywords: head and neck squamous cell carcinoma, radioresistance, DRP1, mitochondrial fission, mitochondrial dynamics, reactive oxygen species, oxidative stress, DNA damage, radiosensitization, Mdivi-1, P110, metabolomics

The starting point of the review is the physical assault that radiotherapy delivers. Ionizing radiation deposits energy that breaks DNA directly and, indirectly, floods cells with reactive oxygen species that damage proteins, lipids, and genomes alike. The dose, the fractionation schedule, and the type of radiation used all determine the character of this pressure. Cells that survive the initial insult do so by activating their DNA damage response machinery, a coordinated network of sensors, transducers, and effectors that pauses the cell cycle, repairs double-strand breaks through pathways such as non-homologous end joining and homologous recombination, and, when damage is overwhelming, triggers senescence or apoptosis. But the review emphasizes that DNA repair is only the first layer of a much deeper program of tolerance.

That deeper program is cellular plasticity. Rather than dying or fully recovering, a subset of surviving cells appears to enter altered, quasi-stable states that echo phenomena described in drug-treated tumors. The authors catalog several of these: persister-like states in which cells reversibly suspend proliferation; cancer stem cell-like states marked by molecules such as CD44 and aldehyde dehydrogenase, with enhanced self-renewal and repair capacity; senescence-like states, detectable in part by senescence-associated beta-galactosidase, in which cells remain metabolically alive but stop dividing and can secrete inflammatory signals; and hybrid epithelial-mesenchymal transition states that combine adhesive and migratory traits. Crucially, these states are not permanent identities. They are plastic, meaning the same residual cell may drift between them, and that fluidity makes them extraordinarily difficult to eliminate with any single targeted agent.

Alongside chromatin remodeling and transcriptional stress memory, which allow cells to carry a kind of biochemical recollection of the radiation they endured, these plastic states form the tumor-cell-intrinsic half of the radioresistance story. The review is careful to note that this intrinsic component complements rather than replaces classical radiosensitivity, which depends on factors such as oxygenation, cell-cycle phase, and repair capacity. What is new is the recognition that intrinsic tolerance alone cannot explain why recurrences so often emerge in predictable locations and time windows. For that, the authors argue, one must look outward, to the microenvironment that surrounds and stabilizes the surviving cells.

The concept of the tolerant niche is the conceptual heart of the paper. The authors describe several recurring microenvironmental configurations that act as sanctuaries for residual disease. Hypoxic niches are perhaps the best known: low oxygen reduces the radiation-induced free radical chemistry that makes oxygen so potent a radiosensitizer, and hypoxia simultaneously drives stem-like and invasive transcriptional programs. Perivascular niches, the zones around surviving blood vessels, shelter quiescent tumor cells and are rich in protective signaling. Niches dominated by cancer-associated fibroblasts and remodeled extracellular matrix provide both mechanical and biochemical support, secreting growth factors and stiffening tissue architecture in ways that dampen radiation lethality. Metabolic niches, shaped by nutrient scarcity and altered metabolite exchange, and myeloid niches, populated by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells that suppress antitumor immunity, complete the picture. In each case, the niche does not merely coexist with tolerant cells; it actively maintains their state.

One of the review’s most useful contributions is its insistence that these mechanisms vary substantially among tumor types. The relative weight of hypoxia, stromal shielding, immune suppression, or stem-like plasticity differs between, for example, glioblastoma, pancreatic ductal adenocarcinoma, and lung cancer, and the authors caution against assuming that a strategy validated in one context will transfer to another. This heterogeneity has practical consequences for how the field measures residual disease. The authors assess the tools available and find them strikingly unequal in maturity. Functional imaging, including hypoxia-targeted PET tracers and advanced MRI sequences, and liquid biopsy based on circulating tumor DNA, offer selected clinical readouts that can already be deployed in trials to track residual disease and recurrence risk over time.

Spatial omics technologies, by contrast, which map gene expression and other molecular features across intact tissue sections, currently serve mainly as discovery and validation tools rather than clinical diagnostics. They are indispensable for identifying which cells occupy which niches and how those relationships change after irradiation, but sampling limitations, cost, and analytical complexity keep them out of routine practice. The review is candid about this gap: the field can describe tolerant niches in exquisite detail in resected specimens, yet it largely lacks the longitudinal, minimally invasive measurements needed to watch them form and dissolve in living patients. Bridging that gap, the authors suggest, will require combining serial ctDNA monitoring with imaging and, where feasible, repeat tissue sampling.

On the therapeutic side, the review outlines both evidence-based and investigational strategies for what the authors term niche-informed radiotherapy. Established approaches include hypoxia modification, dose escalation and altered fractionation, and combinations with DNA damage response inhibitors that disable the repair programs tolerant cells rely on. More speculative candidates target the niche itself: agents that reprogram cancer-associated fibroblasts, normalize tumor vasculature, modulate myeloid suppressor cells, or relieve immune suppression so that checkpoint blockade can act on residual disease. Senolytic strategies aimed at clearing senescence-like cells, and agents designed to push plastic persister states out of their protective equilibrium, also feature among the investigational options. The unifying principle is that candidate combinations should be validated against the specific niche dependencies of a given tumor before clinical adaptation, rather than applied indiscriminately.

The authors are equally clear about the obstacles standing between this framework and the clinic. Conceptually, tolerant niches are dynamic and heterogeneous, so static snapshots may mislead. Sampling remains a fundamental problem, since the most informative regions of a treated tumor are often inaccessible. Implementation faces the usual barriers of combination-therapy trials, toxicity management, and the absence of validated biomarkers that identify which patients carry which niche dependencies. None of these limitations, in the authors’ view, undermines the framework; they simply define the work that remains. The review, which was supported by numerous Chinese national and institutional research programs and published open access on 9 October 2026, is intended as a roadmap rather than a final verdict.

If the tolerant niche concept holds up under experimental and clinical scrutiny, its implications for oncology could be considerable. Recurrence after radiotherapy would no longer be viewed as a mysterious resurgence but as the predictable product of a documented sequence: radiation pressure, followed by the emergence of plastic residual states, followed by their stabilization within hypoxic, stromal, metabolic, and immune sanctuaries. Each step in that sequence offers an interception point, a moment when a rationally chosen combination therapy might extinguish the embers before they reignite. Turning that vision into practice will demand the longitudinal monitoring tools and niche-specific combination trials the review calls for, but it reframes one of radiotherapy’s oldest frustrations as a solvable, spatially defined problem in tumor ecology.

Subject of Research: Radioresistance and tumor recurrence through cellular plasticity and radiation-induced tolerant niches in the tumor microenvironment

Article Title: Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities

Article References: Zhang, Y., Li, H., Lv, S., Peng, L., Meng, W., Guo, J., Lu, Y., Chen, W., Yang, W., & Peng, X. (2026). Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities. Molecular Cancer. https://doi.org/10.1186/s12943-026-02806-3

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02806-3

Keywords: radioresistance, radiotherapy, tumor recurrence, tolerant niches, cellular plasticity, DNA damage response, tumor microenvironment, cancer stem cells, hypoxia, residual disease, spatial omics, ctDNA

The team began by creating laboratory models that faithfully mimic what happens in patients undergoing fractionated radiotherapy. They exposed two head and neck cancer cell lines, OECM1 and Detroit, to repeated rounds of radiation over an extended period, generating isogenic radioresistant sublines. This long-term fractionated irradiation approach is important because clinical radiotherapy is delivered in many small doses over weeks, and acute single-dose experiments can miss the adaptive changes that accumulate during a real treatment course. With these paired sensitive and resistant cell lines in hand, the researchers performed global microRNA profiling to determine which of these small regulatory RNAs change consistently when cells become radioresistant.

MicroRNAs are short, non-coding RNA molecules that regulate gene expression after transcription by binding target messenger RNAs and suppressing their translation or promoting their degradation. A single microRNA can regulate dozens or even hundreds of target genes, which makes them powerful coordinators of cellular behavior. The profiling revealed a remarkably consistent signature: 25 microRNAs were altered in the radioresistant sublines of both cell lines. Twelve were upregulated and behaved as oncogenic microRNAs, or oncomiRs, while thirteen were downregulated and appeared to function as tumor-suppressive microRNAs. The fact that the same signature emerged in two independent cell lines suggested that these changes are not random artifacts but a coordinated program underlying radioresistance.

To understand what this program actually does, the researchers performed integrative target prediction, pathway enrichment analysis, and network construction, linking each microRNA to its predicted messenger RNA targets. The analysis showed that the 25 altered microRNAs converge on a set of oncogenic modules with clear relevance to aggressive cancer biology: receptor tyrosine kinase signaling, cell motility, and stress response and cancer stemness pathways. At the center of the network sat familiar villains of head and neck cancer, including the epidermal growth factor receptor EGFR, the insulin-like growth factor 1 receptor IGF1R, and the transcriptional regulator MYC. The refined network distilled down to 68 microRNA–messenger RNA interaction pairs, with individual microRNAs such as miR-199b-5p and miR-522-3p emerging as key regulatory nodes.

Crucially, the network was not merely a computational exercise. When the researchers ectopically overexpressed the key regulatory microRNAs in head and neck cancer cells, the cells became significantly more sensitive to radiation. This functional validation demonstrated that the microRNA nodes identified through bioinformatics genuinely control radiosensitivity, strengthening the case that the network represents a real biological mechanism rather than a statistical pattern. It also raised an obvious therapeutic question: if a network of microRNAs and their targets maintains radioresistance, could a drug be found that collapses the entire network at once?

Answering that question is where the study takes a particularly modern turn. Rather than screening thousands of compounds blindly, the team turned to transcriptome-guided drug repurposing using the Connectivity Map platform. This approach inverts the traditional drug discovery logic: instead of asking which chemicals kill cancer cells, it asks which approved or investigational drugs produce a gene expression signature opposite to the disease signature of interest. When the radioresistant microRNA–messenger RNA network signature was queried against the drug database, one compound rose decisively to the top: I-OMe-AG-538, an inhibitor of IGF1R, with a strong negative connectivity score of tau equal to minus 87, indicating that the drug’s transcriptional effects run counter to the resistance program.

The choice of IGF1R as the target makes biological sense in light of the network analysis. The receptor sat among the central hubs of the resistance network, and blocking it would be expected to weaken multiple oncogenic modules simultaneously. Experimental validation confirmed this prediction. Treating radioresistant cells with I-OMe-AG-538 dose-dependently suppressed the phosphorylation of IGF1R and its downstream signaling partner Erk, cutting off the growth and survival signals that the receptor transmits. More strikingly, the drug reprogrammed the microRNA landscape itself: oncomiRs that had been elevated in resistant cells were pushed down, while tumor-suppressive microRNAs that had been lost were restored. In effect, the compound nudged the entire regulatory network back toward a radiation-sensitive state.

The drug also attacked a second pillar of radioresistance: redox homeostasis. Ionizing radiation kills cells largely by generating reactive oxygen species, and resistant tumors often survive by scavenging these molecules. I-OMe-AG-538 elevated intracellular reactive oxygen species levels in the treated cells, overwhelming one of the defenses that resistant tumors rely on. In clonogenic assays—the gold-standard test of a cell’s ability to survive radiation and form new colonies—the combination of the drug with irradiation synergistically increased radiosensitivity, meaning the two treatments worked together more powerfully than either alone. Supporting the clinical relevance of these findings, an analysis of The Cancer Genome Atlas head and neck squamous cell carcinoma dataset showed that patients whose tumors expressed high levels of IGF1R had poorer prognosis, and that high IGF1R expression correlated with upregulation of genes that scavenge reactive oxygen species.

The broader significance of the work lies in its strategy. Drug repurposing offers a faster and cheaper route to the clinic than de novo drug development, because repurposed compounds often have established safety profiles. By anchoring the search in a mechanistically defined microRNA–messenger RNA network rather than a generic gene expression profile, the researchers gained both a drug candidate and a biological rationale for why it should work. The study also underscores how microRNAs can serve as both biomarkers and functional mediators of treatment resistance, and how targeting upstream signaling hubs like IGF1R can produce downstream effects across an entire regulatory network, including the microRNA layer itself.

Considerable work remains before patients could benefit. The findings come from cell line models and computational analyses, and the drug’s ability to sensitize tumors in living animals and in combination with standard chemoradiotherapy regimens will need to be demonstrated. Dosing, toxicity, and potential interactions with other receptor tyrosine kinase inhibitors already used in head and neck cancer all require study. Nevertheless, the research provides a coherent roadmap: define the resistance network, validate its key nodes, find a compound that reverses the network’s signature, and confirm that the compound restores radiation sensitivity while disrupting both oncogenic signaling and antioxidant defenses. For patients whose head and neck cancers refuse to yield to radiation, that roadmap offers a genuinely new direction—one in which an old drug, guided by a new map, may help radiation finish the job it was meant to do.

Subject of Research: miRNA–mRNA regulatory network underlying radioresistance in head and neck cancer and transcriptome-guided identification of the IGF1R inhibitor I-OMe-AG-538 as a radiosensitizer

Article Title: Targeting a miRNA–mRNA regulatory network to overcome radioresistance in head and neck cancer: identification of I-OMe-AG-538 via transcriptome-guided drug repurposing

Article References: You, G.-R., Chang, J. T., Huang, H.-H., Shen, E. Y.-L., Chen, Y.-J., Li, Y.-L., & Cheng, A.-J. (2026). Targeting a miRNA–mRNA regulatory network to overcome radioresistance in head and neck cancer: identification of I-OMe-AG-538 via transcriptome-guided drug repurposing. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03357-8

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03357-8

Keywords: head and neck cancer, radioresistance, microRNA, IGF1R, I-OMe-AG-538, drug repurposing, Connectivity Map, radiosensitizer, reactive oxygen species, EGFR, transcriptomics, radiotherapy

The clinical significance of the finding rests on a grim statistical reality. Pancreatic cancer carries one of the lowest five-year survival rates of any malignancy worldwide, and radioresistance remains one of the principal obstacles to effective treatment. In the new study, the team first examined PAFAH1B1 expression in patient tissue using immunohistochemistry, western blotting, and quantitative reverse transcription PCR. They found that the protein was consistently downregulated in pancreatic ductal adenocarcinoma, and that low levels correlated with unfavorable prognosis and poorer response to radiotherapy. In other words, patients whose tumors had less of this protein fared worse when radiation entered the treatment plan, a pattern that immediately suggested PAFAH1B1 might be doing something biologically important beyond its established biochemical role.

PAFAH1B1, formally known as platelet activating factor acetylhydrolase 1b regulatory subunit 1, is not an obscure molecule. It has well-documented functions in cellular physiology, but its connection to radiation response in pancreatic cancer had not been mapped. To probe that connection, the researchers took a practical experimental route: they established two radiation-resistant pancreatic cancer cell lines, derived from the commonly used BxPC-3 and PANC-1 lines, by exposing them to conditions that selected for survival under repeated radiation challenge. They also grew xenograft tumors in mice using the radiation-resistant PANC-1 cells, creating a living model in which the effectiveness of iodine-125 particle therapy could be tested under controlled conditions.

The results were striking. When the team forced PAFAH1B1 overexpression in the radiation-resistant cells, the cells lost much of their defensive capacity. Cell viability and proliferation, measured with CCK-8 assays and colony formation tests, dropped sharply after radiation exposure compared with resistant cells that lacked the extra PAFAH1B1. Flow cytometry revealed shifts in apoptosis as well. Crucially, the same effect appeared in the xenograft model: tumors engineered to overexpress PAFAH1B1 responded better to iodine-125 particle treatment than their resistant counterparts. This demonstrated that the protein’s influence was not an artifact of cell culture but persisted in a whole-animal context, where tumor architecture, blood supply, and immune factors all complicate the picture.

The mechanism behind this sensitization turned out to be ferroptosis, an iron-dependent form of regulated cell death that has attracted intense interest in cancer biology over the past decade. Unlike apoptosis, ferroptosis kills cells through the catastrophic oxidation of lipids in their membranes. It depends on the accumulation of reactive oxygen species and on phospholipids containing polyunsaturated fatty acids, which are particularly vulnerable to peroxidation. When lipid peroxides build up faster than the cell’s antioxidant systems can neutralize them, the membrane disintegrates and the cell dies. The researchers evaluated ferroptosis directly using commercial assay kits and BODIPY 581/591 C11 staining, a fluorescent probe whose signal shifts when it inserts into oxidized lipids, providing a visual and quantitative readout of lipid peroxidation within living cells.

What the staining and assays showed was that PAFAH1B1 overexpression potentiated the ferroptotic response to radiation. Radiation alone damages cells in many ways, including through DNA breaks and free radical generation, but resistant pancreatic cancer cells had apparently learned to buffer or repair that damage. Restoring PAFAH1B1 tipped the balance back toward death by amplifying the lipid peroxidation cascade that defines ferroptosis. This reframes radioresistance in pancreatic cancer not simply as a matter of DNA repair capacity, but as a failure of the tumor to undergo this oxidative form of cell death, a failure that can potentially be corrected by manipulating a single regulatory axis.

That regulatory axis is where the study becomes technically intricate. The researchers asked how PAFAH1B1 levels are controlled in the first place, and the answer lies in the untranslated region at the tail end of its messenger RNA, the 3′ untranslated region or 3′-UTR. This segment of RNA does not code for protein but serves as a landing platform for regulatory molecules. Two microRNAs, miR-421 and miR-301a-3p, bind to this region and suppress PAFAH1B1 production, a classic post-transcriptional silencing mechanism. The team confirmed these interactions using luciferase reporter assays, in which the PAFAH1B1 3′-UTR is fused to a light-producing enzyme so that any change in binding translates into a measurable change in luminescence, and by RNA immunoprecipitation, which physically pulls down protein-RNA complexes to verify who is bound to whom inside cells.

Enter PUM2, or Pumilio 2, an RNA-binding protein with a very different agenda. Rather than silencing the message, PUM2 binds to the same 3′-UTR and stabilizes it, boosting PAFAH1B1 expression. The competitive element is the key insight: PUM2 and the two microRNAs compete for overlapping or adjacent binding sites on the same RNA molecule. When PUM2 occupies the region, it crowds out miR-421 and miR-301a-3p, shielding the transcript from degradation and allowing more PAFAH1B1 protein to be made. The researchers used actinomycin D chase experiments, which block new RNA synthesis so that the decay rate of existing transcripts can be measured, to demonstrate that PUM2 binding extends the lifespan of the PAFAH1B1 message. Through this tug-of-war on a single stretch of RNA, PUM2 effectively overrides the microRNA brake.

The final piece of the puzzle was confirming that PUM2’s pro-ferroptotic effect depends entirely on PAFAH1B1. When the team manipulated PUM2 levels, they found that it promoted radiation-induced ferroptosis, but only when PAFAH1B1 was present to be upregulated. Knock down PAFAH1B1 and PUM2 loses its leverage; restore it and the sensitization returns. This establishes a clean causal chain: PUM2 outcompetes inhibitory microRNAs on the PAFAH1B1 3′-UTR, PAFAH1B1 protein accumulates, radiation-induced lipid peroxidation proceeds unchecked, ferroptosis executes the cell, and iodine-125 particle therapy works as intended. Disrupt any link in that chain, as pancreatic tumors apparently do by downregulating PAFAH1B1, and radioresistance follows.

The translational implications are considerable, though the road from mechanism to medicine is long. The study, supported by the Beijing Nova Program and conducted under ethics approval in accordance with the Declaration of Helsinki and ARRIVE animal guidelines, suggests that strategies to elevate PAFAH1B1, whether by enhancing PUM2 activity, blocking miR-421 and miR-301a-3p, or delivering PAFAH1B1 directly, could convert radiation-resistant pancreatic tumors into treatable ones. It also positions ferroptosis induction as a companion target for iodine-125 seed therapy, which is already used clinically for localized tumor control. For a disease where five-year survival remains the lowest among major cancers, any molecular handle that makes radiation bite harder is worth pursuing, and this PUM2-PAFAH1B1-ferroptosis pathway now offers one of the most mechanistically complete maps of pancreatic cancer radioresistance published to date.

Subject of Research: PUM2-mediated PAFAH1B1 stabilization and ferroptosis in overcoming radioresistance to iodine-125 particle therapy in pancreatic ductal adenocarcinoma

Article Title: PAFAH1B1 stabilization, through PUM2-mediated competitive binding with miRNAs on its’ 3’-UTR, takes active actions on ferroptosis to overcome the radioresistance to 125I radioactive particles of pancreatic ductal adenocarcinoma

Article References: Bi, Y., Shen, W., Ma, C., Tang, A., Jian, K., Jiang, L., Liu, Y., & Min, M. (2026). PAFAH1B1 stabilization, through PUM2-mediated competitive binding with miRNAs on its’ 3’-UTR, takes active actions on ferroptosis to overcome the radioresistance to 125I radioactive particles of pancreatic ductal adenocarcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08948-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08948-8

Keywords: PAFAH1B1, PUM2, ferroptosis, pancreatic ductal adenocarcinoma, radioresistance, iodine-125, microRNA, miR-421, miR-301a-3p, radiosensitivity, RNA-binding protein, 3'-UTR

The molecule in question is PD-1, or programmed cell death protein 1, a receptor best known as the target of the blockbuster class of cancer immunotherapies called immune checkpoint inhibitors. PD-1 normally acts as a molecular brake on immune responses, and tumors exploit this brake by co-opting the PD-1/PD-L1 axis to paralyze cytotoxic T lymphocytes, the immune system’s primary tumor-killing cells. What makes the new findings so provocative is that the researchers found radiotherapy itself, a treatment intended to unleash anti-tumor immunity, drives PD-1 expression onto tumor-associated monocytes, converting these cells into immunosuppressive agents that undermine the very immune attack radiation is supposed to provoke.

Monocytes are circulating white blood cells that can be recruited into tissues, including tumors, where they differentiate into macrophages and related myeloid cells. Within the tumor microenvironment, these myeloid cells often take on a suppressive phenotype, dampening T cell activity and fostering an immunologically cold milieu that resists both immunotherapy and other treatments. The new study demonstrates that after radiotherapy, a distinct subset of tumor-associated monocytes upregulates PD-1, and that these PD-1-positive monocytes actively suppress the anti-tumor activity of CD8-positive T cells, the cytotoxic lymphocytes responsible for recognizing and destroying cancer cells.

Perhaps the most technically significant contribution of the work is the delineation of the signaling pathway that connects radiation to PD-1 induction on monocytes. According to the researchers, radiotherapy triggers the adenosine-A2AR-cAMP-PKA-NF-κB axis. In this cascade, adenosine, a purine nucleoside that accumulates in stressed and damaged tissues, engages the A2A adenosine receptor (A2AR) on the monocyte surface. Receptor activation raises intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA), ultimately engaging the transcription factor NF-κB to drive PD-1 expression. This pathway is a classic example of how tissue damage signals can be hijacked by tumors: adenosine is abundant in the hypoxic, metabolically stressed environment of irradiated tumors, and the study shows that this damage-associated molecule becomes the trigger for an immunosuppressive monocyte program.

The functional consequences of this conversion are substantial. When PD-1-positive monocytes accumulate after radiation, they suppress the activity of CD8-positive T cells, blunting the immune-mediated tumor killing that radiation therapy is known to promote through mechanisms such as immunogenic cell death and antigen release. In other words, radiation delivers a double-edged signal: it damages tumor cells in ways that should alert the immune system, but it simultaneously generates a myeloid cell population that mutes that alert. This may help explain a long-standing puzzle in radiation oncology, namely why the much-discussed abscopal effect, in which localized radiation provokes systemic tumor regression, occurs so rarely in clinical practice.

Critically, the researchers did not stop at mechanistic description. They showed that targeting this PD-1-positive monocyte subset enhanced the efficacy of radiotherapy in their experimental models, suggesting that depleting or inhibiting these cells could convert a partially resistant tumor into one that responds robustly to radiation. This therapeutic implication is significant because it points toward combination strategies: rather than simply escalating radiation doses, which risks toxicity, clinicians could in principle pair standard radiotherapy with agents that prevent monocyte PD-1 induction or eliminate the suppressive subset altogether.

The clinical relevance of the findings received direct support from human tissue analysis. The team examined tissues from patients whose tumors had proven resistant to radiotherapy and found elevated infiltration of PD-1-positive monocytes compared with what would be expected in a responsive setting. This correlation between the presence of the suppressive monocyte subset and treatment failure in patients elevates the work beyond a laboratory observation and suggests that the pathway identified in preclinical models operates in human disease. If validated in larger cohorts, PD-1-positive monocyte infiltration could serve as a biomarker predicting which patients are likely to resist radiotherapy and therefore need combination treatment from the outset.

The study also reframes the ongoing conversation about PD-1 as a therapeutic target. Checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 antibodies were developed to release the brake on T cells, and they have transformed outcomes in melanoma, lung cancer and many other malignancies. But the new findings indicate that PD-1 biology extends beyond T cells: myeloid cells expressing PD-1 after radiation represent a separate, radiation-induced reservoir of immunosuppression. This raises intriguing questions about whether PD-1-targeting drugs exert some of their effects through monocytes rather than exclusively through T cells, and whether patients receiving radiotherapy might benefit from checkpoint blockade precisely because it neutralizes the radiation-induced monocyte program.

From a broader perspective, the work exemplifies a growing appreciation that the success or failure of cancer treatment is decided not only by the intrinsic sensitivity of tumor cells but by the ecosystem surrounding them. The tumor microenvironment is a dense network of immune, stromal and vascular components that respond dynamically to therapy. Radiation-induced cell death releases damage-associated molecular patterns, including adenosine, and the new study shows how one such signal is translated, through a defined receptor-second messenger-transcription factor cascade, into a durable immunosuppressive state. Understanding these feedback loops at the molecular level is essential if combination therapies are to be designed rationally rather than empirically.

For patients and clinicians, the immediate takeaway is one of cautious optimism. The identification of the adenosine-A2AR-cAMP-PKA-NF-κB pathway and the suppressive PD-1-positive monocyte subset it generates offers multiple potential points of intervention, from adenosine receptor antagonists to strategies that deplete the monocyte subset, and the demonstration that targeting these cells boosts radiotherapy efficacy provides a proof of principle. Translating that principle into the clinic will require further validation, safety assessment and well-designed trials, but the study supplies a clear mechanistic target for overcoming one of radiotherapy’s most persistent limitations. As the authors conclude, depleting this distinct immunosuppressive monocyte subset that accumulates after radiation represents a promising strategy to overcome resistance and strengthen anti-tumor immunity, a conclusion that could reshape how radiation oncology and immunotherapy are combined in the years ahead.

Subject of Research: Radiotherapy-induced PD-1 expression on tumor-associated monocytes and its role in immunosuppression and radioresistance

Article Title: Radiotherapy drives PD-1 expression on monocytes to attenuate anti-tumor immunity

Article References: Zhang, J., Chen, C., Mu, Q., Hou, Y., & Zhang, X. (2026). Radiotherapy drives PD-1 expression on monocytes to attenuate anti-tumor immunity. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04519-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04519-4

Keywords: radiotherapy, PD-1, monocytes, tumor microenvironment, radioresistance, CD8-positive T cells, adenosine, A2A receptor, NF-kB, immunotherapy, cancer resistance, myeloid cells

BPIFB1 is a member of the bactericidal permeability-increasing fold-containing family, a group of innate immune proteins whose members share a structural architecture evolved to bind lipids and engage microbial targets. The protein is abundantly expressed in the nasopharyngeal epithelium, the very tissue from which nasopharyngeal carcinoma arises, which makes its behavior in this cancer particularly consequential. According to the review, BPIFB1 is markedly downregulated in nasopharyngeal carcinoma tissues, and loss of its expression is associated with poor prognosis for patients. In other words, the more the molecule disappears from tumor cells, the worse the clinical outlook tends to be, a correlation that has prompted researchers to classify it as a tumor suppressor.

What makes the story compelling from a viral oncology standpoint is the mechanism behind that loss. The review highlights accumulating evidence that BPIFB1 is directly targeted and suppressed by EBV-encoded miR-BART4, one of the microRNAs the virus produces during latent infection. Epstein–Barr virus is known to maintain its long-term residence in infected cells in part by deploying a panel of BART microRNAs, which fine-tune both viral and host gene expression without provoking strong immune detection. By steering miR-BART4 at BPIFB1, the virus appears to strip the epithelium of one of its local sentinels, a maneuver that could undermine both the tissue’s barrier functions and its capacity to coordinate immune responses.

The authors frame BPIFB1 as a multi-node tumor suppressor, a description that captures the unusual breadth of its influence. Rather than acting through a single pathway, the molecule is implicated in regulating several of the classic hallmarks of cancer simultaneously. These include immune escape, the process by which tumor cells avoid recognition and destruction by cytotoxic lymphocytes; metastatic invasion, the acquisition of motile and tissue-infiltrating behavior that allows cancer cells to spread; and glycolytic reprogramming, the metabolic shift toward heightened glucose fermentation even in the presence of oxygen, known as the Warburg effect, which supports rapid proliferation.

The reach of BPIFB1 extends further still. The review identifies roles for the molecule in modulating radioresistance, a phenomenon of particular clinical relevance in nasopharyngeal carcinoma, where radiotherapy is a mainstay of treatment and tumor cells that withstand radiation drive treatment failure. BPIFB1 also appears to influence cell proliferation directly and to engage inflammation-associated signaling, including pathways centered on NF-kappaB, a transcription factor family that sits at the hub of inflammatory responses and is frequently co-opted in malignancy. Chronic inflammation in the tumor microenvironment is widely recognized as a driver of cancer progression, and a molecule capable of tempering those signals could in principle slow multiple aspects of tumor evolution at once.

An intriguing theme running through the review is that BPIFB1 does not behave identically in every tissue. The authors describe tissue-specific functional heterogeneity across multiple tumor types, citing evidence from breast, lung and gastric cancers in addition to nasopharyngeal carcinoma. This kind of context dependence is increasingly appreciated in cancer biology: a protein that suppresses growth in one epithelium may have more nuanced or even opposing effects elsewhere, depending on the local repertoire of interacting partners, signaling pathways and metabolic conditions. For researchers hoping to translate BPIFB1 findings into the clinic, this heterogeneity is a caution as well as an opportunity, since any therapeutic strategy would need to account for how the molecule behaves in the specific tissue being treated.

To situate these functional findings mechanistically, the review systematically summarizes the molecular structure of BPIFB1 and the regulatory mechanisms underlying its aberrant expression in cancer. The protein belongs to the PLUNC subfamily, which is expressed selectively in the upper airways and is thought to participate in the mucosal defense of these surfaces, contributing to the antimicrobial and anti-inflammatory properties of airway secretions. That lineage makes evolutionary sense of the molecule’s dual character: it is simultaneously an innate immune effector shaped for mucosal surveillance and, according to the evidence assembled by the Changsha team, a regulator of intracellular signaling circuits that tumors exploit for survival and spread.

Beyond cancer, the review casts a wider net, surveying recent advances in BPIFB1-related research across multi-system diseases. This broader framing reflects a growing recognition that innate immune molecules of the airway are not narrowly specialized anti-bacterial agents but participants in systemic biology, with potential relevance wherever epithelial barriers, mucosal immunity and inflammatory signaling intersect. The disease geography of nasopharyngeal carcinoma itself underscores the point, since the tight association between EBV and this tumor in specific populations suggests that host genetic and environmental factors modulating mucosal immunity may shape risk in ways that a single-virus, single-tissue perspective would miss.

On the translational front, the authors discuss BPIFB1’s potential as both a biomarker and a therapeutic target. As a biomarker, the molecule’s consistent downregulation in nasopharyngeal carcinoma and its association with poor prognosis suggest that measuring its expression could help stratify patients or track disease behavior. As a therapeutic target, the challenge is thornier, because restoring a suppressed tumor suppressor inside malignant cells is far more difficult than inhibiting an overactive oncogene. Yet the viral connection offers a conceptual foothold: if EBV-encoded miR-BART4 is the principal driver of BPIFB1 loss, strategies aimed at blunting that microRNA or counteracting its downstream effects could, in principle, reawaken the suppressed protein. The open-access review, which was published on 25 September 2026 and supported by the Project of Changsha Natural Science Foundation, does not claim such interventions exist today; it consolidates the mechanistic groundwork that would make them conceivable.

For a cancer that remains a major burden in Southern China and Southeast Asia, and for the broader field of virus-associated malignancy, the synthesis offered by Cai and colleagues is a reminder that the tumor microenvironment is shaped as much by what the immune system loses as by what the tumor gains. BPIFB1, a molecule of the airway’s first line of defense, emerges from this review as a lens through which viral manipulation, metabolic reprogramming, inflammatory signaling and immune evasion can be seen as a single connected story. Whether future work can convert that mechanistic insight into clinical tools, from prognostic assays to microRNA-targeted therapies, will depend on validating these roles across cohorts and disease settings, but the review makes a clear case that this underappreciated epithelial protein deserves a prominent place on the research agenda for nasopharyngeal carcinoma and beyond.

Subject of Research: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1 in nasopharyngeal carcinoma

Article Title: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases

Article References: Cai, J., Jiang, F., Xiao, L., & Zhang, W. (2026). Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04580-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04580-z

Keywords: BPIFB1, LPLUNC1, nasopharyngeal carcinoma, Epstein-Barr virus, miR-BART4, tumor suppressor, immunomodulation, glycolytic reprogramming, radioresistance, NF-kappaB, innate immunity, multi-system diseases

Ionizing radiation kills cells primarily by generating DNA double-strand breaks, the most lethal form of genetic damage. Cells respond with two principal repair strategies: homologous recombination, which operates in the S and G2 phases of the cell cycle and uses an intact sister chromatid as a template, and non-homologous end joining, which is available throughout the cell cycle and directly ligates broken DNA ends. The Ku heterodimer, composed of the Ku70 and Ku80 proteins, sits at the very front line of non-homologous end joining. It recognizes broken DNA ends within seconds of their formation, encircles the free DNA terminus like a sliding clamp, and recruits the downstream enzymatic machinery needed to process and rejoin the break. Without Ku, double-strand breaks accumulate, chromosomal aberrations multiply, and cells become exquisitely sensitive to radiation.

The new research reveals that the assembly of the Ku70-Ku80 heterodimer itself is not a spontaneous, unregulated event but a process actively promoted by a complex containing TIMELESS and SIRT1. TIMELESS, best known for its role in maintaining circadian clocks and stabilizing replication forks, had previously been implicated in the DNA damage response, but its precise contribution to double-strand break repair remained murky. The study now positions TIMELESS as a scaffold that brings together SIRT1 and Ku70, creating a microenvironment in which Ku70 is kept in a state favorable for pairing with its partner Ku80. SIRT1, an NAD-dependent deacetylase, modifies Ku70 by removing acetyl groups, a chemical change that appears to facilitate the proper folding and interaction of Ku70 with Ku80 and with damaged DNA.

Using a combination of co-immunoprecipitation, proximity ligation assays, and live-cell imaging of DNA repair factor recruitment, the investigators demonstrated that cells lacking TIMELESS or SIRT1 show a marked deficit in Ku heterodimer formation. When the researchers depleted TIMELESS, Ku70 failed to associate efficiently with Ku80, and the recruitment of Ku to laser-induced DNA damage tracks was visibly delayed. The same phenotype emerged when SIRT1 was inhibited pharmacologically or knocked down genetically, indicating that the deacetylase activity of SIRT1 is a functional requirement, not merely a passive component of the complex. Rescue experiments in which wild-type SIRT1 was reintroduced restored Ku assembly, whereas catalytically inactive SIRT1 mutants did not, pinpointing the enzymatic activity as the decisive factor.

The consequences for radiation sensitivity were striking. Cancer cells deficient in TIMELESS or SIRT1 accumulated more residual double-strand breaks after irradiation, displayed elevated levels of chromosome breaks and micronuclei, and died at substantially higher rates following clinically relevant doses of radiation. Conversely, cells engineered to overexpress the TIMELESS-SIRT1-Ku70 module became more resistant, repairing radiation-induced breaks faster and surviving doses that killed their normal counterparts. The effect was specific to the Ku pathway: markers of homologous recombination were largely unaffected, suggesting that the complex operates selectively on non-homologous end joining rather than globally boosting all forms of DNA repair.

What makes this discovery particularly compelling is the cast of characters involved. SIRT1 has long fascinated biologists because of its links to calorie restriction, aging, and metabolism, and pharmacological SIRT1 activators have been pursued as potential anti-aging therapeutics. TIMELESS connects the study to the circadian clock, raising the tantalizing possibility that the daily rhythm of a cell’s repair capacity may be governed, at least in part, by the oscillating availability of this complex. Clinicians have long observed that the timing of radiotherapy within the day can influence outcomes in some cancers, and a molecular bridge between clock proteins and DNA repair machinery offers a plausible mechanistic underpinning for such observations. If TIMELESS abundance or activity fluctuates with the cell’s internal clock, the efficiency of Ku assembly, and therefore of end joining, might fluctuate with it.

For oncology, the immediate implication is that the TIMELESS-SIRT1-Ku70 axis represents a candidate target for radiosensitization. Drugs that disrupt the complex, inhibit SIRT1’s deacetylase activity in tumors, or prevent the recruitment of Ku to broken DNA could strip cancer cells of a key survival advantage and make radiation therapy more effective at lower doses. This matters because dose escalation is often limited by damage to surrounding healthy tissue; a radiosensitizer that preferentially compromises tumor cell repair would widen the therapeutic window. The study’s demonstration that SIRT1 inhibition phenocopies TIMELESS loss is especially encouraging from a translational standpoint, since SIRT1 inhibitors already exist as research tools and are being explored in other disease contexts.

The findings also carry a cautionary note for interpreting tumor biology. High levels of TIMELESS have been reported in several malignancies and have been associated with poor prognosis, an observation often attributed to the protein’s role in supporting replication stress tolerance and cell proliferation. The new work adds a second, complementary explanation: tumors that overexpress TIMELESS may also be intrinsically more resistant to radiotherapy because their Ku assembly machinery runs at full throttle. This could help explain why some patients with seemingly similar tumors respond dramatically differently to the same radiation regimen, and it suggests that TIMELESS expression levels might serve as a biomarker for predicting radiosensitivity and guiding treatment decisions.

As with any mechanistic study, important questions remain. The precise structural details of how TIMELESS docks onto Ku70 and how SIRT1’s deacetylation of Ku70 alters the heterodimer’s DNA-binding properties will require biochemical and structural characterization. It is also not yet clear whether the complex acts at the break site itself or in the nucleoplasm before Ku ever encounters damaged DNA, and whether additional factors participate in the assembly process. Translating the findings into the clinic will demand evidence that the axis operates in human tumors in vivo and that its disruption does not catastrophically sensitize normal tissues, which also rely on Ku-mediated repair to survive radiation. Nonetheless, by illuminating a previously hidden regulatory step in one of the cell’s most fundamental repair pathways, the study opens a concrete new avenue for making radiation therapy work harder against cancer, and it reinforces a growing theme in modern oncology: the most effective treatments may come not from hitting tumors harder, but from quietly dismantling the molecular machinery that lets them endure.

Subject of Research: A TIMELESS-SIRT1-Ku70 protein complex that promotes Ku heterodimer assembly and confers radioresistance to cancer cells through enhanced non-homologous end joining DNA repair.

Article Title: A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly

Article References: Di, L., Gu, J., Xie, Z., Liu, Q., Huang, J., He, X., Chen, F., Meng, Q., Qian, J., Zhou, Y., Shu, Y., Chen, X., Zhang, W., Lu, X., Zhang, J., Tian, Y., Zhu, Q., Wang, W., Leung, C.-H., & Zhu, W.-G. (2026). A TIMELESS-SIRT1-Ku70 complex confers radioresistance to cancer cells by promoting Ku heterodimer assembly. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03363-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03363-w

Keywords: TIMELESS, SIRT1, Ku70, Ku80, DNA double-strand breaks, non-homologous end joining, radioresistance, radiation therapy, DNA repair, circadian clock, cancer, radiosensitization

To capture that transformation in motion, the team did something many earlier studies failed to do. Rather than relying on the human cell lines that dominate the radioresistance literature, lines that are poorly suited to immunocompetent systems and therefore blind researchers to the immune dimension of treatment failure, the investigators generated radioresistant isogenic variants of murine lung adenocarcinoma cell lines. Because these variants are genetically matched to their radiation-sensitive parents, any differences that emerge after repeated irradiation can be attributed to adaptive changes rather than pre-existing genetic background. The team then interrogated these paired models using transcriptomics, three-dimensional co-culture systems, and syngeneic mouse models that retain fully functioning immune systems.

The results paint a picture of tumors that have reorganized themselves at multiple levels simultaneously. The radioresistant clones displayed stable adaptations to DNA damage, including enhanced clonogenic survival after irradiation and constitutive activation of DNA damage response pathways, with the ATR pathway, named for the ataxia telangiectasia and Rad3-related kinase, standing out as particularly active. ATR functions as a master regulator of the cellular response to replication stress and DNA damage, and its persistent activation appears to give cancer cells a cushion against the strand breaks that ionizing radiation inflicts. Critically, the clinical relevance of this observation was not left to speculation: analyzing data from non-small cell lung cancer patients, the researchers found that high ATR levels were significantly associated with immunosuppression, linking a tumor-intrinsic survival mechanism to a hostile immune environment in human disease.

The transcriptomic analysis uncovered a second layer of the adaptation. Radioresistant tumors showed altered DNA repair programs alongside a marked downregulation of type-I interferon signaling and innate immune pathways. This is a crucial detail because radiation therapy, in addition to directly damaging DNA, is supposed to function as an in situ vaccine. When tumor cells die from irradiation, they are expected to undergo immunogenic cell death, releasing damage-associated molecular patterns that activate the cGAS-STING sensing axis and other innate pathways, which in turn recruit and activate cytotoxic T cells capable of finishing off survivors. By dampening these pathways, radioresistant tumors essentially mute the alarm system that radiation depends on to alert the immune system, reducing immunogenic cell death and converting what should be an inflammatory dying process into a quiet one.

The consequences of that muting were visible throughout the tumor microenvironment. In syngeneic mice, radioresistant tumors recruited a distinctly immunosuppressive cellular cast: increased numbers of T regulatory cells, M2-like macrophages, and myeloid-derived suppressor cells, along with reduced recruitment of cytotoxic T lymphocytes. These cell types are well-known accomplices of tumor survival, suppressing antitumor immunity through a variety of inhibitory signals and metabolic depletion. The three-dimensional co-culture experiments added a functional confirmation: when immunosuppressive cells were present alongside cancer cells in the same culture, they protected the malignant cells from radiation-induced cytotoxicity. In other words, the immune cells that radioresistant tumors attract are not bystanders. They are active participants in treatment failure, forming a shield that absorbs or suppresses the immune attack that radiation is meant to provoke.

Perhaps the most striking evidence for the centrality of immune suppression came from a transplant experiment of sorts. When the same radioresistant tumors were grown in immunodeficient mice, animals lacking the adaptive and innate immune machinery that normally shields the tumor, they regained their sensitivity to radiotherapy. Stripped of their immunosuppressive entourage, the tumors that had been so resilient in immunocompetent hosts became vulnerable again. This single observation reframes the entire problem of radioresistance: a substantial portion of it is not written into the cancer cell’s genome at all, but is instead conferred by the ecosystem the tumor has cultivated around itself.

That reframing immediately suggested therapeutic possibilities, and the team pursued them with encouraging results. The first approach involved artificially kick-starting innate immunity using agonists of Toll-like receptors, specifically the combination of poly(I:C), which activates TLR3, and R848, which targets TLR7 and TLR8. When these agonists were delivered to radioresistant tumors, they restored antitumor responses and improved the efficacy of radiotherapy, in part through a mechanism centered on the chemokines CXCL9 and CXCL10. These chemokines act as beacons for immune cells, and their induction re-established the recruitment of cytotoxic immune cells into the tumor, effectively rebuilding the alarm system that the radioresistant clones had dismantled. The findings give the study its title and its conceptual core: CXCL9-driven immune rewiring can restore the conditions under which radiation therapy works as intended.

The second approach attacked the problem from inside the cancer cell. Using ceralasertib, a pharmacological inhibitor of ATR, the researchers sensitized radioresistant tumors to radiation, directly undermining the constitutive DNA damage response activation that had given the cells their survival cushion. Together with the innate immune agonists, this establishes a rationale for combined strategies that hit both halves of the radioresistance program at once: stripping away the tumor’s molecular repair capacity with ATR inhibition while simultaneously reigniting the immune recruitment signals that allow radiation to trigger a lasting antitumor response. Neither approach alone represents a complete solution, but the logic of the combination, grounded in the mechanistic findings rather than empirical trial and error, is what distinguishes this work from earlier attempts to sensitize tumors to radiation.

The broader implications reach beyond lung cancer. The study demonstrates that the way radioresistance research is conducted matters: models lacking intact immune systems systematically obscure the contribution of the microenvironment, and this team’s decision to build isogenic immunocompetent models paid off with insights that would have been invisible in conventional systems. For clinicians treating non-small cell lung cancer, the work suggests that markers such as ATR expression and chemokine signatures could eventually help identify patients at risk of locoregional relapse before it occurs, and that combining radiotherapy with TLR agonists or ATR inhibitors deserves serious clinical evaluation. For now, the findings rest on preclinical evidence, and the usual caveats about translation from mice to humans apply. But they offer something that has been in short supply in this field: a mechanistically coherent account of how tumors learn to shrug off radiation, and a map of the vulnerabilities created along the way. As radiotherapy continues to anchor the treatment of lung cancer worldwide, strategies that restore rather than replace its power may prove to be the key to preventing the relapses that have long defied the beam.

Subject of Research: Mechanisms of radioresistance in non-small cell lung cancer involving ATR signaling and immune microenvironment rewiring

Article Title: CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer

Article References: Leon, S., Otegui, N., Redrado, M., Marchena-Perea, E. M., Guruceaga, E., Castro, F., Montuenga, L. M., Oliveira, M. J., Aristu, J. J., Serrano, D., & Calvo, A. (2026). CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03834-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03834-z

Keywords: radiotherapy, non-small cell lung cancer, radioresistance, ATR inhibitor, ceralasertib, CXCL9, tumor microenvironment, immunosuppression, TLR agonists, innate immunity, DNA damage response, cancer immunotherapy

The research, led by investigators at Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, centres on kinesin family member C1, or KIFC1, a motor protein best known for hauling cargo along microtubules and for its role in centrosome clustering during cell division. By mining six publicly available transcriptomic datasets of cervical cancer, the team found that KIFC1 was among the most significantly dysregulated kinesin genes in tumour tissue compared with healthy cervical tissue. Pan-cancer analysis across more than twenty tumour types confirmed widespread overexpression, and examination of clinical databases linked elevated KIFC1 to lymph node metastasis. Crucially, the findings were not confined to computational correlations: immunohistochemical staining of a tissue microarray containing 115 cervical carcinoma specimens and 39 adjacent non-tumour tissues showed markedly higher KIFC1 protein levels in tumours, and patients whose tumours expressed high levels of the protein experienced significantly poorer disease-free and overall survival.

To probe what KIFC1 actually does inside cervical cancer cells, the researchers engineered HeLa and SiHa cell lines with stable KIFC1 knockdown or overexpression using lentiviral vectors. The functional consequences were striking. Depleting KIFC1 curtailed cell proliferation in cell counting and colony formation assays and impaired migration in wound healing and Transwell experiments, while forcing KIFC1 expression produced the opposite effects, enhancing growth and motility. But the most revealing clue came from RNA sequencing of KIFC1-silenced cells, which identified 2,714 differentially expressed genes. Pathway enrichment analysis pointed strongly toward metabolic reprogramming, with glycolysis and gluconeogenesis among the most significantly affected processes. Direct biochemical measurements confirmed the shift: glucose consumption, lactate production and intracellular ATP levels all fell when KIFC1 was silenced and rose when it was overexpressed, hallmarks of the Warburg effect that tumour cells exploit to fuel rapid proliferation.

The mechanistic thread connecting KIFC1 to metabolism runs through pyruvate kinase M, or PKM, the enzyme that catalyses the final, rate-limiting step of glycolysis. The PKM gene undergoes alternative splicing to yield two isoforms with opposing metabolic roles: PKM1 supports oxidative metabolism, whereas PKM2 favours aerobic glycolysis and is the dominant form in most tumours. When the researchers examined isoform expression after KIFC1 knockdown, they found PKM2 levels dropped while PKM1 rose, indicating that KIFC1 helps maintain the pro-glycolytic PKM2 balance that cervical cancer cells depend upon. The question was how a microtubule motor protein could influence a splicing decision buried in the cell’s gene-expression machinery.

The answer emerged from an unbiased proteomic approach. Using co-immunoprecipitation coupled with mass spectrometry, the team catalogued 1,067 proteins that physically associate with KIFC1, and among the enriched functional categories were spliceosome components and mRNA splicing processes. One candidate stood out: SRSF3, a serine/arginine-rich splicing factor previously shown to promote inclusion of PKM exon 10 and thereby tilt splicing toward PKM2. Co-immunoprecipitation experiments confirmed that KIFC1 and SRSF3 interact in cervical cancer cells, and database analysis revealed a robust correlation between the two genes in patient tumours. Intriguingly, KIFC1 knockdown did not change total SRSF3 abundance. Instead, nuclear and cytoplasmic fractionation combined with confocal immunofluorescence microscopy showed that depleting KIFC1 reduced the amount of SRSF3 in the nucleus and increased its cytoplasmic accumulation, suggesting that the motor protein acts as a shuttle that delivers the splicing factor to its site of action rather than as a regulator of its production.

Follow-up experiments cemented SRSF3 as the functional intermediary. Silencing SRSF3 in HeLa and SiHa cells suppressed proliferation, migration and all three glycolytic readouts, mirroring the effects of KIFC1 depletion. RNA immunoprecipitation demonstrated that SRSF3 binds directly to PKM messenger RNA, and its loss reproduced the isoform shift, raising PKM1 and lowering PKM2. Most persuasively, rescue experiments showed that restoring SRSF3 in KIFC1-depleted cells partially reversed the suppression of proliferation, migration, glucose consumption, lactate production and ATP generation, and re-established the PKM2-dominant profile. Taken together, these results delineate a coherent KIFC1–SRSF3–PKM axis in which a transport motor governs the subcellular localisation of a splicing factor, which in turn dictates a metabolic enzyme isoform switch that sustains the glycolytic appetite of the tumour.

What elevates this finding from an interesting piece of cell biology to a potentially transformative therapeutic insight is its connection to radiotherapy. Aerobic glycolysis is increasingly recognised as a driver of radioresistance because it supplies the energy and biosynthetic intermediates needed for DNA repair and helps tumour cells buffer the oxidative stress inflicted by radiation. When the researchers exposed KIFC1-silenced cells to graded doses of irradiation, clonogenic survival dropped significantly, particularly at 4 Gy and above, and radiation-induced apoptosis increased. Pharmacological activation of PKM2 with the selective activator TEPP-46 partially restored proliferative capacity and blunted the apoptotic response, demonstrating that the radiosensitising effect of KIFC1 loss depends on PKM2-driven glycolysis. Restoring SRSF3 produced a similar partial rescue, confirming the pathway’s role in the radiation response.

DNA damage assays provided a mechanistic window into why glycolytic disruption sensitises cells to radiation. After 4 Gy irradiation, KIFC1-depleted cells displayed elevated γ-H2AX fluorescence, a marker of DNA double-strand breaks, along with increased 53BP1 recruitment and reduced RAD51 foci, indicating impaired homologous recombination repair. Both SRSF3 restoration and TEPP-46 treatment partially reversed these changes, reinforcing the idea that a glycolysis-competent state is required for tumour cells to mend radiation-induced damage efficiently. The team then translated these findings into vivo using subcutaneous xenografts in nude mice. KIFC1 knockdown alone suppressed tumour growth, and combining it with a 6 Gy focal dose of irradiation produced significantly slower tumour growth than either intervention alone, accompanied by reduced Ki-67 staining and the same PKM isoform shift observed in culture. The authors candidly note that the in vivo effect was one of tumour growth delay rather than complete regression, a discrepancy they attribute to the complexity of the tumour microenvironment, including hypoxia, stromal interactions and the metabolic plasticity that allows tumours to compensate by activating alternative energy pathways.

The study does carry limitations that the authors themselves acknowledge. Validation in larger clinical cohorts will be needed to firmly establish KIFC1 as a prognostic and predictive biomarker, the precise splicing sites mediating SRSF3’s control of PKM in cervical cancer were not directly mapped, and the molecular determinants of the KIFC1–SRSF3 interaction, including possible adaptor proteins, remain to be identified. Nevertheless, the work expands the functional repertoire of KIFC1 well beyond mitosis, revealing a post-transcriptional mechanism by which intracellular transport machinery shapes metabolic adaptation and therapeutic resistance. If pharmacological inhibitors of this axis can be developed or repurposed, clinicians may one day combine them with radiotherapy to strip cervical tumours of the metabolic armour that currently lets them survive treatment, offering new hope for patients whose disease has stopped responding to conventional care.

Subject of Research: The role of the KIFC1–SRSF3–PKM splicing–metabolic axis in cervical cancer glycolysis and radiosensitivity

Article Title: Targeting the KIFC1‐SRSF3‐PKM Axis Suppresses Cervical Cancer Glycolysis and Enhances Radiosensitivity

Article References: Liu, J., Li, J., Zhou, H., Ha, W., Wu, X., Liu, X., Jiang, Y., Gong, C., Cheng, Y., Liu, Q., Chao, T., & Xiong, H. (2026). Targeting the KIFC 1‐ SRSF 3‐ PKM Axis Suppresses Cervical Cancer Glycolysis and Enhances Radiosensitivity. Journal of Cellular and Molecular Medicine, 30(18), Article e71373. https://doi.org/10.1111/jcmm.71373

Image Credits: AI Generated

DOI: 10.1111/jcmm.71373

Keywords: cervical cancer, KIFC1, SRSF3, PKM2, glycolysis, radioresistance, alternative splicing, Warburg effect, DNA damage repair, kinesin motor protein, radiosensitivity, tumour metabolism